MoonLake's CEO expresses confidence in 120mg being the optimal dose and highlights the drug's improved durability of response compared to Humira in other studies.
The long stock would be$Bruush Oral Care(BRSH.US)$. First its goal is to regain compliance over a 1.00. Second it has a new line of products to boost its next ER. Third the upside beats the downside. 500% in gains. The short stock would be$MoonLake Immunotherapeutics(MLTX.US)$It has just seen its highest run. Once it gets above 50.00 its loses investors interest.
$MoonLake Immunotherapeutics (MLTX.US)$ I have this skin condition, Hopefully they keep having good results with their medication. Hopefully this stock really flies again off this news.
MoonLake Immunotherapeutics股票討論區
$Leap Therapeutics(LPTX.US)$ Phase 2
$Vera Therapeutics(VERA.US)$ Phase 2b
$4D Molecular Therapeutics(FDMT.US)$ Phase 2
$Adverum Biotechnologies(ADVM.US)$ Phase 2
$Denali Therapeutics(DNLI.US)$ Phase 2
$Akero Therapeutics(AKRO.US)$ Phase 2b
$Spruce Biosciences(SPRB.US)$ Phase 2
$Xencor(XNCR.US)$ Phase 2
$阿里拉姆制藥(ALNY.US)$ Phase 2
$Harmony Biosciences(HRMY.US)$ Phase 2
$Annexon(ANNX.US)$ Phase 2a
$Roivant Sciences(ROIV.US)$...
$Regenxbio(RGNX.US)$ Phase 2
$Leap Therapeutics(LPTX.US)$ Phase 2
$4D Molecular Therapeutics(FDMT.US)$ Phase 2
$Adverum Biotechnologies(ADVM.US)$ Phase 2
$Denali Therapeutics(DNLI.US)$ Phase 2
$EyePoint Pharmaceuticals(EYPT.US)$ Phase 2
$Xencor(XNCR.US)$ Phase 2
$Harmony Biosciences(HRMY.US)$ Phase 2
$阿里拉姆制藥(ALNY.US)$ Phase 2
$Disc Medicine(IRON.US)$ Phase 2
$Atea Pharmaceuticals(AVIR.US)$ Phase 2
$Allakos(ALLK.US)$ Phase 2...
The short stock would be $MoonLake Immunotherapeutics(MLTX.US)$ It has just seen its highest run. Once it gets above 50.00 its loses investors interest.
暫無評論